What is Chronic pain Phase 3 Study oxycodone/naltrexone (OxyTrex)?

Category: Others

false

This is a Phase 3, 12-Month, Open-Label, Single-Arm, Safety Study of a combination of extended-release oxycodone combined with low-dose naltrexone for patients with chronic non-cancer pain. Other names include: NCT01428583, ALO-02-10-3001, B4531001.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
0
Moderate
0
Mild
0
None
1

Commonly reported side effects and conditions associated with Chronic pain Phase 3 Study oxycodone/naltrexone (OxyTrex)

Side effect Patients

Why patients stopped taking Chronic pain Phase 3 Study oxycodone/naltrexone (OxyTrex)

Multiple reasons could be selected

Reason Patients
Course of treatment ended 1
Did not seem to work 1
See all 2 patients who've stopped taking Chronic pain Phase 3 Study oxycodone/naltrexone (OxyTrex)

Duration

Stopped taking Chronic pain Phase 3 Study oxycodone/naltrexone (OxyTrex)

Duration Patients
1 - 2 years 1
5 - 10 years 1
Adherence
Adherence Evaluations
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Last updated:
There are no evaluations for Chronic pain Phase 3 Study oxycodone/naltrexone (OxyTrex).